EUVIMEDEUVIMED entdecken
Crossref

The cervical cancer screening program in the North of Portugal: Outcomes after nearly two decades of coexistence with the human papillomavirus vaccine

Patrícia Sá iD, Paula Monteiro, Rui Henrique, Nuno Lunet iD

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70196 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Patrícia Sá und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health and Forensic Sciences, and Medical Education, Faculty of Medicine, University of Porto, Porto, Portugal. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Papillomavirus Vaccines, Early Detection of Cancer, Papillomavirus Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As the first vaccinated cohorts are gradually becoming eligible for cervical cancer screening (CCS), changes in the distribution of high‐risk human papillomavirus (hrHPV) infection and associated disease endpoints are expected to occur. We aimed to describe the clinical outcomes of the Regional CCS Program of the North of Portugal in the latest years and to estimate the impact of different hrHPV genotypes on the occurrence of cervical neoplasia. Secondary data collected from the Regional CCS Program of the North of Portugal between January 2019 and December 2024 was used. Descriptive analysis was performed, and the proportion of high‐grade squamous intraepithelial lesion (≥HSIL) attributable to different hrHPV genotypes was estimated. Between January 2022 and December 2024, the prevalence of hrHPV infection was 14.1%, and multiple infections accounted for 28.4% of the cases. Overall, the most prevalent genotypes were HPV‐68 (16.6%), HPV‐52 (14.5%), and HPV‐31 (13.3%). Among the samples that underwent cytological analysis, 14.8% were atypical squamous cells of undetermined significance, 7.2% were low‐grade squamous intraepithelial lesion, and 3.9% were ≥HSIL. Between 2019 and 2024, there was a decrease in the prevalence of the hrHPV genotypes included in the quadrivalent vaccine (17.5%–11.4%), especially in the youngest females, who also experienced a decrease in the frequency of ≥HSIL (6.0%–2.4%). The proportion of ≥HSIL attributable to these hrHPV types decreased from 38.5% to 23.5% in the youngest females, and no significant variations were found for the remaining. This study highlights the considerable reduction of the prevalence of both hrHPV infection and associated cervical abnormalities among the youngest and presumably vaccinated cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsPapillomavirus VaccinesEarly Detection of CancerPapillomavirus InfectionsUterine Cervical DysplasiaHumansFemalePortugalAdultMiddle AgedPapillomaviridaeGenotypePrevalenceAgedYoung AdultMass Screening

Stichwörter der Autor:innen

cervical cancer screeningcervical neoplasiahuman papillomavirusvaccine

Substanzen

Papillomavirus Vaccines

Autor:innen und Institutionen

  • Department of Public Health and Forensic Sciences, and Medical Education, Faculty of Medicine, University of Porto, Porto, Portugal.
  • Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC Raquel Seruca), Porto, Portugal.
  • Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Po…
  • Department of Pathology and Molecular Immunology, ICBAS-School of Medicine & Biomedical Sciences, University of Porto, Porto, Portugal.
  • Associate Laboratory for Integrative and Translational Research in Population Health (ITR)-Epidemiology Research Unit (EPIUnit), Institute of Public Health, University of Porto, Porto, Portugal.

ORCID-Profile: Patrícia Sá, Nuno Lunet

Zitieren

APA

Sá, P., Monteiro, P., Henrique, R., & Lunet, N. (2026). The cervical cancer screening program in the North of Portugal: Outcomes after nearly two decades of coexistence with the human papillomavirus vaccine. International Journal of Cancer. https://doi.org/10.1002/ijc.70196

Vancouver

Sá P, Monteiro P, Henrique R, Lunet N. The cervical cancer screening program in the North of Portugal: Outcomes after nearly two decades of coexistence with the human papillomavirus vaccine. International Journal of Cancer. 2026. doi:10.1002/ijc.70196

BibTeX
@article{S2026,
  author = {Sá, Patrícia and Monteiro, Paula and Henrique, Rui and Lunet, Nuno},
  title = {The cervical cancer screening program in the North of Portugal: Outcomes after nearly two decades of coexistence with the human papillomavirus vaccine},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70196}
}
Kostenlos starten →